Roger Breslin

[Roger Breslin @RogerBreslin]

Dom Amore: How UConn softball handled the blows and clawed back to the NCAA Tournament https://t.co/CucHDUH4x1

[Roger Breslin @RogerBreslin]

https://t.co/dWtI07HYTT

[Roger Breslin @RogerBreslin]

https://t.co/iFPT1hkZjs

[Roger Breslin @RogerBreslin]

Help us take F&M Athletics to new heights - join me in supporting Raise Our Game! Go Dips! #DipsRaiseOurGame https://t.co/BKNQ72Ike0

[Roger Breslin @RogerBreslin]

Tech Company Expands Downtown Office Lease To 125K SF: The Boston Deal Sheet https://t.co/HMabMIULu7

[Roger Breslin @RogerBreslin]

JLL names Sam Schaefer as CEO of Property Management https://t.co/p1ld0UNWXH

[UConn Softball @UConnSoftball]

The Huskies are off to Baton Rouge!

Thanks for sending us off @JonathanHusky_ 💙

[UConn Softball @UConnSoftball]

🚨𝐅𝐑𝐄𝐒𝐇𝐌𝐀𝐍 𝐎𝐅 𝐓𝐇𝐄 𝐘𝐄𝐀𝐑🚨

Cat Petteys is your @BIGEAST Freshman of the Year‼️

[UConn Softball @UConnSoftball]

🚨𝐏𝐋𝐀𝐘𝐄𝐑 𝐎𝐅 𝐓𝐇𝐄 𝐘𝐄𝐀𝐑🚨

Grace Jenkins is your @BIGEAST Player of the Year‼️

[Roger Breslin @RogerBreslin]

Softball Standout Kaitlyn Breslin Receives National Recognition https://t.co/dQ3ZvaKEOe

[Roger Breslin @RogerBreslin]

https://t.co/HbbmXQb0EM

[Roger Breslin @RogerBreslin]

https://t.co/AWZbTAyy6y

[Roger Breslin @RogerBreslin]

ESPN shuffles content exec team structure https://t.co/Nxt8HBvi9O via @sbj

[PureTech @PureTechH]

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease.

Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF.

We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability.

A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership.

Read more in today’s press release: https://t.co/OF2QBhBfin

[Roger Breslin @RogerBreslin]

https://t.co/cv3WnJtpMD

[Roger Breslin @RogerBreslin]

Join me and make a gift to Giving Tuesday 2024 https://t.co/5cbT5f8eqI

[Roger Breslin @RogerBreslin]

Join me and make a gift to Giving Tuesday 2024 https://t.co/5cbT5f8eqI

[Roger Breslin @RogerBreslin]

https://t.co/MSQmp6jVhg

[Roger Breslin @RogerBreslin]

This school in Worcester is now teaching girls for the first time https://t.co/fMi9YO6rVW

[Roger Breslin @RogerBreslin]

Appreciation: Ronald S. Perry leaves a giant legacy at Catholic Memorial, Holy Cross https://t.co/FJprl4mCaR